Profiles

Keywords
Last Name
Institution

James Moy

Concepts (173)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Asthma
18
2021
182
2.550
Why?
Antibodies, Viral
4
2022
79
1.220
Why?
Immunoglobulins, Intravenous
4
2018
25
1.170
Why?
Immunoglobulin G
5
2021
134
1.100
Why?
Immunologic Deficiency Syndromes
3
2017
12
0.960
Why?
Agammaglobulinemia
2
2018
4
0.920
Why?
Antibody Formation
1
2021
33
0.920
Why?
Common Variable Immunodeficiency
2
2018
7
0.910
Why?
Bacterial Infections
3
2018
71
0.870
Why?
Genetic Diseases, X-Linked
1
2018
1
0.730
Why?
Immunoglobulins
1
2017
35
0.690
Why?
Immunologic Factors
1
2017
53
0.670
Why?
Immunotherapy
1
2017
74
0.660
Why?
Child, Preschool
12
2019
786
0.650
Why?
Adrenal Cortex Hormones
5
2019
100
0.540
Why?
Child
12
2021
1572
0.540
Why?
Glucocorticoids
4
2019
77
0.520
Why?
Respiratory Sounds
2
2019
11
0.460
Why?
Bronchodilator Agents
3
2019
14
0.440
Why?
Alendronate
2
2019
8
0.400
Why?
Ibuprofen
2
2021
12
0.390
Why?
Adolescent
9
2019
2667
0.380
Why?
Humans
32
2022
31481
0.380
Why?
Female
22
2021
18253
0.370
Why?
Male
21
2021
17583
0.370
Why?
Adult
13
2021
9779
0.360
Why?
Double-Blind Method
9
2021
559
0.340
Why?
Anti-Asthmatic Agents
4
2018
35
0.330
Why?
Administration, Inhalation
7
2019
37
0.320
Why?
Young Adult
6
2019
2277
0.320
Why?
Middle Aged
10
2021
11209
0.300
Why?
Cockroaches
1
2003
1
0.270
Why?
Respiratory Hypersensitivity
1
2003
5
0.270
Why?
Eosinophilia
2
2017
49
0.270
Why?
Allergens
1
2003
20
0.270
Why?
Acetaminophen
3
2021
20
0.260
Why?
Sputum
2
2019
23
0.240
Why?
Pandemics
2
2021
203
0.220
Why?
Lung
2
2019
171
0.210
Why?
Infant
6
2018
642
0.210
Why?
Immunity, Innate
1
2021
97
0.210
Why?
Prospective Studies
4
2019
1934
0.210
Why?
Adrenergic beta-2 Receptor Agonists
1
2019
3
0.200
Why?
Education, Medical, Continuing
1
2020
47
0.200
Why?
Cohort Studies
3
2021
2014
0.200
Why?
Hypersensitivity
1
2020
54
0.200
Why?
Receptors, Adrenergic, beta-2
1
2019
8
0.200
Why?
Vitamin A Deficiency
1
2018
1
0.190
Why?
Vitamin A
1
2018
8
0.190
Why?
Contrast Sensitivity
1
2018
8
0.190
Why?
Randomized Controlled Trials as Topic
1
2021
375
0.190
Why?
Eosinophils
1
2019
47
0.190
Why?
Zinc
1
2018
40
0.190
Why?
Arginine
1
2018
17
0.180
Why?
Glutathione
1
2018
31
0.180
Why?
Drug-Related Side Effects and Adverse Reactions
1
2018
34
0.180
Why?
Coronavirus Infections
1
2020
97
0.180
Why?
Pneumonia, Viral
1
2020
102
0.170
Why?
Leukotriene Antagonists
1
2016
1
0.170
Why?
Inhalation Exposure
2
2008
6
0.160
Why?
Azithromycin
1
2015
3
0.160
Why?
Respiratory Tract Infections
1
2015
25
0.150
Why?
Treatment Outcome
4
2018
3910
0.150
Why?
Secondary Prevention
1
2015
67
0.150
Why?
Research Design
3
2021
238
0.140
Why?
Pregnenediones
1
2014
3
0.140
Why?
Cholecalciferol
1
2014
3
0.140
Why?
Vitamins
1
2014
11
0.140
Why?
Vitamin D Deficiency
1
2014
11
0.140
Why?
Recurrence
3
2016
389
0.130
Why?
Cotinine
2
2011
6
0.120
Why?
Anti-Bacterial Agents
1
2015
412
0.120
Why?
African Americans
1
2019
818
0.120
Why?
Dose-Response Relationship, Drug
3
2019
512
0.120
Why?
Quality of Life
1
2017
663
0.120
Why?
Dermatitis, Allergic Contact
1
2011
7
0.110
Why?
Pruritus
1
2011
15
0.110
Why?
Silicones
1
2011
14
0.110
Why?
Peritoneal Dialysis
1
2011
27
0.110
Why?
Catheters, Indwelling
1
2011
30
0.110
Why?
Severity of Illness Index
3
2021
1240
0.110
Why?
Mexican Americans
1
2011
28
0.110
Why?
Follow-Up Studies
3
2018
2028
0.100
Why?
Sensitivity and Specificity
2
2022
580
0.100
Why?
Smoking
1
2011
202
0.100
Why?
Cross-Over Studies
2
2019
82
0.100
Why?
Prevalence
2
2018
544
0.100
Why?
Tobacco Smoke Pollution
1
2008
8
0.090
Why?
Saliva
1
2008
62
0.090
Why?
Leukocyte Count
2
2019
96
0.090
Why?
Aged
3
2018
10295
0.090
Why?
Case-Control Studies
2
2021
687
0.090
Why?
Albuterol
2
2018
17
0.090
Why?
Models, Biological
1
2008
428
0.080
Why?
Cross-Sectional Studies
3
2018
986
0.080
Why?
Quinolines
1
2005
18
0.080
Why?
Acetates
1
2005
26
0.080
Why?
Incidence
2
2018
829
0.070
Why?
Pyroglyphidae
1
2003
1
0.070
Why?
Air Pollution, Indoor
1
2003
2
0.070
Why?
Skin Tests
1
2003
16
0.070
Why?
Urban Health
1
2003
29
0.070
Why?
Cats
1
2003
79
0.070
Why?
Child Welfare
1
2003
21
0.070
Why?
Statistics as Topic
1
2003
124
0.070
Why?
Dogs
1
2003
283
0.060
Why?
Respiratory Syncytial Viruses
1
2002
1
0.060
Why?
Chemokines
1
2002
31
0.060
Why?
Serologic Tests
1
2022
15
0.060
Why?
Clinical Trials, Phase II as Topic
1
2021
30
0.060
Why?
NF-kappa B
1
2002
112
0.060
Why?
Advisory Committees
1
2021
48
0.060
Why?
Clinical Protocols
1
2021
75
0.060
Why?
Immunization, Passive
1
2021
20
0.060
Why?
Seroepidemiologic Studies
1
2021
22
0.060
Why?
Receptors, Fc
1
2021
10
0.060
Why?
Complement Activation
1
2021
14
0.060
Why?
Immunoglobulin M
1
2021
21
0.060
Why?
Immunoglobulin Fc Fragments
1
2021
10
0.060
Why?
Spike Glycoprotein, Coronavirus
1
2021
17
0.060
Why?
Antibody Specificity
1
2021
59
0.060
Why?
Antibody-Dependent Cell Cytotoxicity
1
2021
24
0.060
Why?
Gene Expression Regulation, Neoplastic
1
2002
136
0.060
Why?
Antibodies, Neutralizing
1
2021
26
0.060
Why?
Phagocytosis
1
2021
52
0.060
Why?
Tumor Necrosis Factor-alpha
1
2002
230
0.050
Why?
Education, Distance
1
2020
18
0.050
Why?
Administration, Oral
2
2014
164
0.050
Why?
United States
2
2018
2539
0.050
Why?
Drug Combinations
1
2019
88
0.050
Why?
Adrenergic beta-Antagonists
1
2019
45
0.050
Why?
Inflammation
1
2021
360
0.050
Why?
Peak Expiratory Flow Rate
1
2018
2
0.050
Why?
Ornithine
1
2018
3
0.050
Why?
Growth
1
2018
6
0.050
Why?
Medication Adherence
1
2019
93
0.050
Why?
Analgesics, Non-Narcotic
1
2018
18
0.040
Why?
Reproducibility of Results
1
2021
886
0.040
Why?
Forced Expiratory Volume
1
2017
13
0.040
Why?
Immunoglobulin E
1
2017
17
0.040
Why?
Tomography, X-Ray Computed
1
2021
891
0.040
Why?
Fever
1
2016
38
0.040
Why?
Chicago
2
2011
955
0.040
Why?
Neutrophils
1
2017
133
0.040
Why?
Kaplan-Meier Estimate
1
2016
230
0.040
Why?
Drug Resistance, Bacterial
1
2015
55
0.040
Why?
Phenotype
1
2017
379
0.040
Why?
Drug Administration Schedule
1
2015
257
0.040
Why?
Treatment Failure
1
2014
187
0.030
Why?
Animals
1
2003
5312
0.030
Why?
Pain
1
2016
336
0.030
Why?
Disease Progression
1
2015
861
0.030
Why?
Patch Tests
1
2011
2
0.030
Why?
Exanthema
1
2011
15
0.030
Why?
Morbidity
1
2011
71
0.030
Why?
Half-Life
1
2009
19
0.030
Why?
Drug Dosage Calculations
1
2009
7
0.030
Why?
Regression Analysis
1
2011
319
0.030
Why?
Drug Evaluation
1
2009
58
0.030
Why?
Kidney Failure, Chronic
1
2011
176
0.020
Why?
Socioeconomic Factors
1
2008
362
0.020
Why?
Sulfides
1
2005
13
0.020
Why?
Adrenergic beta-Agonists
1
2005
20
0.020
Why?
Cyclopropanes
1
2005
27
0.020
Why?
Placebos
1
2005
89
0.020
Why?
Acetylcysteine
1
2002
11
0.020
Why?
Free Radical Scavengers
1
2002
13
0.020
Why?
Tumor Cells, Cultured
1
2002
155
0.010
Why?
Oxidation-Reduction
1
2002
79
0.010
Why?
Dexamethasone
1
2002
52
0.010
Why?
Antiviral Agents
1
2002
139
0.010
Why?
Signal Transduction
1
2002
588
0.010
Why?
Lung Neoplasms
1
2002
756
0.010
Why?
Moy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description